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BRIEFING No.1 
Research findings from Innogen  
 
 
 
   
 
 
 
 
 
 
 
 
 
 
 
Public Private Partnerships (PPPs) in the area of health are currently the focus of considerable debate. They 
are seen by some as a way of overcoming the crisis of ‘neglected diseases’ and the fact that 90% of the 
world’s spending on health-related research benefits only 10% of its population. A workshop hosted by the 
ESRC Genomics Forum and attended by policy experts, practitioners and academics examined the role of 
global PPPs (GPPPs) in developing new drugs and vaccines designed to combat diseases that are common in 
poorer countries1.  This policy brief focuses on two issues highlighted at the workshop. Participants felt these 
issues require the attention of policy makers if GPPPs are to be successful in the long-term. 
 
PPPS ARE INNOVATIVE: PRODUCING NEW TECHNOLOGIES AND BUILDING CAPACITY 
GPPPs have generated new drug development initiatives focussed on the needs of the world’s poor. A 
number of these operate with relative autonomy from large public sector or multi-lateral bureaucracies. They 
are relatively flexible and responsive to changing and complex environments. For example, the International 
Aids Vaccine Initiative (IAVI) and the South African Aids Vaccine Initiative (SAAVI) have been particularly 
adept at global and local advocacy work. They have brought into focus the ways in which science and 
technology might be used to address the needs of people in poorer countries. 
In the case of AIDS, although a vaccine has yet to emerge, IAVI has nevertheless made a substantial 
contribution to capacity building in developing countries. This is an important observation because capacity 
building is not part of IAVI’s mission even though it is a strategic necessity. Particularly in Africa, real 
achievements have been made in the areas of scientific and technological capabilities – including competence 
to prepare and carry out clinical trials. Because such initiatives cut across traditional boundaries and systems, 
such as public and private, health and industrial sectors, a broad range of capacities can be built through 
product oriented activity. For example, with IAVI’s assistance, Rwanda, Kenya and Uganda have developed 
potential centres of excellence in vaccine clinical trials. 
Product development GPPPs offer valuable ways forward in producing vaccines and in capacity building in 
developing countries. However, the success of GPPPs is rooted in how they link to a variety of other 
organisations and institutions. This broader institutional and organisational context and the broader capacity 
building benefits should not be ignored. While PPPs may offer one option, they are not the only alternative.  
 
MAINTAINING A BROADER PERSPECTIVE AND A BALANCE OF METHODOLOGICAL ISSUES 
Workshop participants expressed concern that narrow approaches may lead to short-term formulas but may 
miss the point. For example, current discussions about the role of advanced purchase agreements, tax credits 
and other incentives for private sector involvement are likely to deliver appealing policy recommendations. But 
the formulas will be based on narrow assumptions that economic ‘pull’ policy mechanisms will resolve 
underlying problems. GPPPs are embedded within societal structures. The development of PPPs and the 
extent to which they are able to offer solutions to the development and diffusion of vaccines will be affected by 
a broad range of social, cultural and political issues not simply those of an economic nature. 
There is considerable evidence that organisational capacities and broader institutional mechanisms are as 
important in creating constructive participation in drug development. An important consideration, for example, 
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is that many private sector companies have withdrawn from vaccines development because profit prospects 
were unappealing. The loss of expertise and capacities to produce vaccines will not be restored via financial 
incentives alone. 
A range of other perspectives and methodologies can provide additional research and recommendations that 
will lead to more rounded and viable solutions. Historical work on vaccine development can provide insights 
into success and failure in past vaccine development. In particular, historical analysis suggests that the public 
sector may have an essential role to play in maintaining expertise in areas which are critical over the longer 
term. Additionally, a sociological framework can provide perspective on the role of the private and public 
sectors in sustaining the development and delivery of appropriate vaccines over the longer term.  
This mix of methodologies can be used to examine a wider range of issues particularly in relation to health 
systems delivery capacity that need thorough consideration if new drugs are to be effectively diffused as well 
as developed. Maintaining a broader perspective and methodological framework will provide better 
opportunities for a full range of expertise to be engaged in planning for product development and delivery 
within local contexts. The implication here is that funding for GPPPs should not substitute for supporting a 
range of actors needed to deliver drugs and services to the world’s poor.   
 
CONCLUSIONS 
GPPPs offer exciting opportunities and the best deserve further funding. This funding, however, needs to be 
delivered in ways that reinforce the involvement of a range of actors. Not all funding oriented towards 
developing new vaccines and drugs can be channelled into GPPPs. More active involvement of private sector 
companies, although welcome, is unlikely to deliver a panacea to the problem of bridging the gap between 
modern bioscience and applications essential to the majority of the world’s population. Funding needs to be 
channelled to GPPPs but balanced with additional funding for a range of science-based organisations, 
particularly perhaps public sector laboratories and private and public sector organisations and institutions 
engaged with product diffusion and delivery. 
 
NOTES 
1
 Workshop on “Making vaccines work for the poor: Are public private partnerships the answer?” held at ESRC Genomics Policy and 
Research Forum, University of Edinburgh, December 13
th
-14
th
 2004. For a full list of attendees see www.innogen.ac.uk/events 
 
 
 
 
 
 
 
 
 
 
EGN research ranges across the whole field of genomics, covering areas as diverse as plant and 
animal genetics, embryonic stem cell research, and associated health applications. 
 
The Network ranges across five of the UK’s leading universities, and involves over a hundred researchers, from professors to PhD 
students, as well as administrative and support staff and an international cast of visiting research fellows. It is one of the largest social 
science investments in the ESRC’s current portfolio, and is growing into the largest concentration of social scientific research on 
genomics in the world. 
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